Clinical research is at the heart of all medical advances and contributes greatly to improving the quality of medicine that is available to you and your loved ones. Participants in research studies — people just like you — are a critical link in making these discoveries possible.
Austin Regional Clinic is currently enrolling patients in the below studies. Both ARC patients and non-ARC patients who fit trial eligibility requirements are welcome to apply.
ARC Clinical Research enrolling studies
- Sanofi PSK05 Clinical Study: A phase III, randomized, modified double-blind, active-controlled, parallel-group, two-arm study to investigate the safety of a four-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers.
- VAX 31-201 Pediatric Pneumococcal Clinical Study: A phase II, randomized-double, active-controlled, dose-finding clinical study to evaluate the safety, tolerability, and immunogenicity of VAX-31 in healthy infants given four doses at two, four, six, and 12-15 months of age concomitantly with routine pediatric vaccines.
- BaxDuo Pacific Chronic Kidney Disease (CKD) Clinical Study: A phase III, randomized, double-blind, active-controlled study intended to assess the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on CKD progression and cardiovascular events in participants with CKD and high blood pressure.
- ENABLE Multiple Sclerosis (MS) Clinical Study: A long-term observational registry study for patients with MS to collect real-world data on BRIUMVI (infusion medication) and assess efficacy, safety, and tolerability of medication.
All enrolling studies.
Learn more by calling ARC Clinical Research at 737-247-7240 or visit ARCclinicalresearch.com.